U.S. FDA approves Bayer drug Aliqopa

U.S. FDA approves Bayer drug Aliqopa (copanlisib) for follicular lymphoma


Bayer recently won U.S. FDA approval to market its oncology drug Aliqopa (copanlisib) for the treatment of follicular lymphoma.

Company : Bayer

For Treatment of : Follicular lymphoma

Therapeutic Areas : Hematology, Oncology



General Information of Aliqopa (copanlisib)

 Aliqopa (copanlisib) is a kinase inhibitor with activity predominantly against the PI3K-alpha and PI3K-delta isoforms expressed in malignant B cells.


Aliqopa is specifically indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies. 


Aliqopa is supplied as a solution for intravenous infusion. The recommended dose is 60 mg administered as a 1-hour intravenous infusion on Days 1, 8, and 15 of a 28-day treatment cycle on an intermittent schedule (three weeks on and one week off). Continue treatment until disease progression or unacceptable toxicity.